Sanofi (SNW BE) stock market data APIs
€81.4909
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
Sanofi Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for SNW.BE.
Prev. Close
81.4909
Open
81.4909
High
81.4909
Low
81.4909
52 wk Range
78.48-105.4891
Market Cap
108 619 M
EPS
1.79
Dividends (Yield)
0.0361
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sanofi data using free add-ons & libraries
Get Sanofi Fundamental Data
Sanofi Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-24
- EPS/Forecast: 1.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sanofi News
New
Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market
TAIPEI and SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492, "Senhwa") today announced its official entry into the fast-growing global immuno-oncology market. The Company...
Leerink Partners Maintains a Buy Rating on Sanofi (SNY)
Sanofi (NASDAQ:SNY) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 6, Leerink Partners analyst David Risinger maintained a Buy rating on Sanofi (NASDAQ:SNY) without a pr...
Sanofi: Information concerning the total number of voting rights and shares - August 2025
Sanofi Winthrop Industrie Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and articl...
Novartis Catches a ‘Sell.’ Goldman Sachs Says the Stock Is Overvalued.
Stock in one of the world’s largest pharmaceutical companies, Novartis fell after Goldman Sachs said its valuation looks stretched and reminded investors that patents are expiring on some of the com...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
